Global Gesagliflozin Market Growth 2026-2032
The global Gesagliflozin market size is predicted to grow from US$ 29.35 million in 2025 to US$ 160 million in 2032; it is expected to grow at a CAGR of 12.7% from 2026 to 2032.
In 2025, global Garsorasib production reached approximately 5000 units.Garsorasib Tablets (generic name: Garsorasib Tablets, trade name: Anfangning) is an independently developed oral small-molecule targeted antineoplastic drug in China for the treatment of KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC), belonging to irreversible KRAS G12C inhibitors. Its mechanism of action is to specifically bind and lock the inactive conformation of the mutant KRAS protein, block the abnormal activation of the downstream MAPK signaling pathway, thereby inhibiting tumor cell proliferation and inducing tumor cell apoptosis. This product is a 200 mg yellow oval film-coated tablet, approved for marketing in China in November 2024. It is mainly indicated for adult patients with locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer who have received at least one prior systemic therapy. It serves as an important domestic innovative targeted drug in the field of precision therapy for lung cancer in China.
Garsorasib, as the second KRAS G12C inhibitor approved in China, occupies an important position in the underserved niche market of KRAS G12C-mutant non-small cell lung cancer, relying on the strong commercialization capability of Chia Tai Tianqing. With its inclusion in medical insurance and the successive launch of multiple domestic similar drugs (Fuzolasib, Golorasib, Jilemei), the market has shifted from an early 'blue ocean' to a fiercely competitive stage. Its core advantages lie in domestic innovation, definite efficacy and favorable safety. In addition, price reduction through medical insurance negotiations has rapidly improved patient accessibility. In the future, market competition will focus on price, medical insurance coverage, clinical efficacy, combination therapy, indication expansion (such as colorectal cancer) and commercial channels. Relying on its first-mover advantage, medical insurance coverage and strong channels, Garsorasib is expected to maintain a stable share among similar domestic products, while facing challenges including price wars, medical insurance cost control and intensified competition from rival drugs.
LP Information, Inc. (LPI) ' newest research report, the ?Gesagliflozin Industry Forecast? looks at past sales and reviews total world Gesagliflozin sales in 2025, providing a comprehensive analysis by region and market sector of projected Gesagliflozin sales for 2026 through 2032. With Gesagliflozin sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gesagliflozin industry.
This Insight Report provides a comprehensive analysis of the global Gesagliflozin landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Gesagliflozin portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Gesagliflozin market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gesagliflozin and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gesagliflozin.
This report presents a comprehensive overview, market shares, and growth opportunities of Gesagliflozin market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Gesagliflozin market?
What factors are driving Gesagliflozin market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Gesagliflozin market opportunities vary by end market size?
How does Gesagliflozin break out by Type, by Application?
In 2025, global Garsorasib production reached approximately 5000 units.Garsorasib Tablets (generic name: Garsorasib Tablets, trade name: Anfangning) is an independently developed oral small-molecule targeted antineoplastic drug in China for the treatment of KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC), belonging to irreversible KRAS G12C inhibitors. Its mechanism of action is to specifically bind and lock the inactive conformation of the mutant KRAS protein, block the abnormal activation of the downstream MAPK signaling pathway, thereby inhibiting tumor cell proliferation and inducing tumor cell apoptosis. This product is a 200 mg yellow oval film-coated tablet, approved for marketing in China in November 2024. It is mainly indicated for adult patients with locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer who have received at least one prior systemic therapy. It serves as an important domestic innovative targeted drug in the field of precision therapy for lung cancer in China.
Garsorasib, as the second KRAS G12C inhibitor approved in China, occupies an important position in the underserved niche market of KRAS G12C-mutant non-small cell lung cancer, relying on the strong commercialization capability of Chia Tai Tianqing. With its inclusion in medical insurance and the successive launch of multiple domestic similar drugs (Fuzolasib, Golorasib, Jilemei), the market has shifted from an early 'blue ocean' to a fiercely competitive stage. Its core advantages lie in domestic innovation, definite efficacy and favorable safety. In addition, price reduction through medical insurance negotiations has rapidly improved patient accessibility. In the future, market competition will focus on price, medical insurance coverage, clinical efficacy, combination therapy, indication expansion (such as colorectal cancer) and commercial channels. Relying on its first-mover advantage, medical insurance coverage and strong channels, Garsorasib is expected to maintain a stable share among similar domestic products, while facing challenges including price wars, medical insurance cost control and intensified competition from rival drugs.
LP Information, Inc. (LPI) ' newest research report, the ?Gesagliflozin Industry Forecast? looks at past sales and reviews total world Gesagliflozin sales in 2025, providing a comprehensive analysis by region and market sector of projected Gesagliflozin sales for 2026 through 2032. With Gesagliflozin sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gesagliflozin industry.
This Insight Report provides a comprehensive analysis of the global Gesagliflozin landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Gesagliflozin portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Gesagliflozin market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gesagliflozin and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gesagliflozin.
This report presents a comprehensive overview, market shares, and growth opportunities of Gesagliflozin market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- 100mg
- 200mg
- Garsorasib and Immune Checkpoint Inhibitors
- Garsorasib and FAK Inhibitors
- Innovator
- Generic
- Hospital
- Retail
- Online
- KRAS G12C-Mutant Tumors
- Non-Small Cell Lung Cancer (NSCLC)
- Colorectal Cancer
- Pancreatic Cancer
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- InventisBio
- Shanghai Chia Tai Tianqing Pharmaceutical
- WuXi AppTec Pharmaceutical
What is the 10-year outlook for the global Gesagliflozin market?
What factors are driving Gesagliflozin market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Gesagliflozin market opportunities vary by end market size?
How does Gesagliflozin break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Gesagliflozin Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Gesagliflozin by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Gesagliflozin by Country/Region, 2021, 2025 & 2032
2.2 Gesagliflozin Segment by Type
2.2.1 100mg
2.2.2 200mg
2.2.3 Gesagliflozin Sales by Type
2.2.3.1 Global Gesagliflozin Sales Market Share by Type (2021-2026)
2.2.3.2 Global Gesagliflozin Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Gesagliflozin Sale Price by Type (2021-2026)
2.3 Gesagliflozin Segment by Combination Therapy
2.3.1 Garsorasib and Immune Checkpoint Inhibitors
2.3.2 Garsorasib and FAK Inhibitors
2.3.3 Gesagliflozin Sales by Combination Therapy
2.3.3.1 Global Gesagliflozin Sales Market Share by Combination Therapy (2021-2026)
2.3.3.2 Global Gesagliflozin Revenue and Market Share by Combination Therapy (2021-2026)
2.3.3.3 Global Gesagliflozin Sale Price by Combination Therapy (2021-2026)
2.4 Gesagliflozin Segment by Production Technology
2.4.1 Innovator
2.4.2 Generic
2.4.3 Gesagliflozin Sales by Production Technology
2.4.3.1 Global Gesagliflozin Sales Market Share by Production Technology (2021-2026)
2.4.3.2 Global Gesagliflozin Revenue and Market Share by Production Technology (2021-2026)
2.4.3.3 Global Gesagliflozin Sale Price by Production Technology (2021-2026)
2.5 Gesagliflozin Segment by Sales Channels
2.5.1 Hospital
2.5.2 Retail
2.5.3 Online
2.5.4 Gesagliflozin Sales by Sales Channels
2.5.4.1 Global Gesagliflozin Sales Market Share by Sales Channels (2021-2026)
2.5.4.2 Global Gesagliflozin Revenue and Market Share by Sales Channels (2021-2026)
2.5.4.3 Global Gesagliflozin Sale Price by Sales Channels (2021-2026)
2.6 Gesagliflozin Segment by Application
2.6.1 KRAS G12C-Mutant Tumors
2.6.2 Non-Small Cell Lung Cancer (NSCLC)
2.6.3 Colorectal Cancer
2.6.4 Pancreatic Cancer
2.6.5 Others
2.6.6 Gesagliflozin Sales by Application
2.6.6.1 Global Gesagliflozin Sale Market Share by Application (2021-2026)
2.6.6.2 Global Gesagliflozin Revenue and Market Share by Application (2021-2026)
2.6.6.3 Global Gesagliflozin Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Gesagliflozin Breakdown Data by Company
3.1.1 Global Gesagliflozin Annual Sales by Company (2021-2026)
3.1.2 Global Gesagliflozin Sales Market Share by Company (2021-2026)
3.2 Global Gesagliflozin Annual Revenue by Company (2021-2026)
3.2.1 Global Gesagliflozin Revenue by Company (2021-2026)
3.2.2 Global Gesagliflozin Revenue Market Share by Company (2021-2026)
3.3 Global Gesagliflozin Sale Price by Company
3.4 Key Manufacturers Gesagliflozin Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Gesagliflozin Product Location Distribution
3.4.2 Players Gesagliflozin Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR GESAGLIFLOZIN BY GEOGRAPHIC REGION
4.1 World Historic Gesagliflozin Market Size by Geographic Region (2021-2026)
4.1.1 Global Gesagliflozin Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Gesagliflozin Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Gesagliflozin Market Size by Country/Region (2021-2026)
4.2.1 Global Gesagliflozin Annual Sales by Country/Region (2021-2026)
4.2.2 Global Gesagliflozin Annual Revenue by Country/Region (2021-2026)
4.3 Americas Gesagliflozin Sales Growth
4.4 APAC Gesagliflozin Sales Growth
4.5 Europe Gesagliflozin Sales Growth
4.6 Middle East & Africa Gesagliflozin Sales Growth
5 AMERICAS
5.1 Americas Gesagliflozin Sales by Country
5.1.1 Americas Gesagliflozin Sales by Country (2021-2026)
5.1.2 Americas Gesagliflozin Revenue by Country (2021-2026)
5.2 Americas Gesagliflozin Sales by Type (2021-2026)
5.3 Americas Gesagliflozin Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Gesagliflozin Sales by Region
6.1.1 APAC Gesagliflozin Sales by Region (2021-2026)
6.1.2 APAC Gesagliflozin Revenue by Region (2021-2026)
6.2 APAC Gesagliflozin Sales by Type (2021-2026)
6.3 APAC Gesagliflozin Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Gesagliflozin by Country
7.1.1 Europe Gesagliflozin Sales by Country (2021-2026)
7.1.2 Europe Gesagliflozin Revenue by Country (2021-2026)
7.2 Europe Gesagliflozin Sales by Type (2021-2026)
7.3 Europe Gesagliflozin Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Gesagliflozin by Country
8.1.1 Middle East & Africa Gesagliflozin Sales by Country (2021-2026)
8.1.2 Middle East & Africa Gesagliflozin Revenue by Country (2021-2026)
8.2 Middle East & Africa Gesagliflozin Sales by Type (2021-2026)
8.3 Middle East & Africa Gesagliflozin Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Gesagliflozin
10.3 Manufacturing Process Analysis of Gesagliflozin
10.4 Industry Chain Structure of Gesagliflozin
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Gesagliflozin Distributors
11.3 Gesagliflozin Customer
12 WORLD FORECAST REVIEW FOR GESAGLIFLOZIN BY GEOGRAPHIC REGION
12.1 Global Gesagliflozin Market Size Forecast by Region
12.1.1 Global Gesagliflozin Forecast by Region (2027-2032)
12.1.2 Global Gesagliflozin Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Gesagliflozin Forecast by Type (2027-2032)
12.7 Global Gesagliflozin Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 InventisBio
13.1.1 InventisBio Company Information
13.1.2 InventisBio Gesagliflozin Product Portfolios and Specifications
13.1.3 InventisBio Gesagliflozin Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 InventisBio Main Business Overview
13.1.5 InventisBio Latest Developments
13.2 Shanghai Chia Tai Tianqing Pharmaceutical
13.2.1 Shanghai Chia Tai Tianqing Pharmaceutical Company Information
13.2.2 Shanghai Chia Tai Tianqing Pharmaceutical Gesagliflozin Product Portfolios and Specifications
13.2.3 Shanghai Chia Tai Tianqing Pharmaceutical Gesagliflozin Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Shanghai Chia Tai Tianqing Pharmaceutical Main Business Overview
13.2.5 Shanghai Chia Tai Tianqing Pharmaceutical Latest Developments
13.3 WuXi AppTec Pharmaceutical
13.3.1 WuXi AppTec Pharmaceutical Company Information
13.3.2 WuXi AppTec Pharmaceutical Gesagliflozin Product Portfolios and Specifications
13.3.3 WuXi AppTec Pharmaceutical Gesagliflozin Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 WuXi AppTec Pharmaceutical Main Business Overview
13.3.5 WuXi AppTec Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Gesagliflozin Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Gesagliflozin by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Gesagliflozin by Country/Region, 2021, 2025 & 2032
2.2 Gesagliflozin Segment by Type
2.2.1 100mg
2.2.2 200mg
2.2.3 Gesagliflozin Sales by Type
2.2.3.1 Global Gesagliflozin Sales Market Share by Type (2021-2026)
2.2.3.2 Global Gesagliflozin Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Gesagliflozin Sale Price by Type (2021-2026)
2.3 Gesagliflozin Segment by Combination Therapy
2.3.1 Garsorasib and Immune Checkpoint Inhibitors
2.3.2 Garsorasib and FAK Inhibitors
2.3.3 Gesagliflozin Sales by Combination Therapy
2.3.3.1 Global Gesagliflozin Sales Market Share by Combination Therapy (2021-2026)
2.3.3.2 Global Gesagliflozin Revenue and Market Share by Combination Therapy (2021-2026)
2.3.3.3 Global Gesagliflozin Sale Price by Combination Therapy (2021-2026)
2.4 Gesagliflozin Segment by Production Technology
2.4.1 Innovator
2.4.2 Generic
2.4.3 Gesagliflozin Sales by Production Technology
2.4.3.1 Global Gesagliflozin Sales Market Share by Production Technology (2021-2026)
2.4.3.2 Global Gesagliflozin Revenue and Market Share by Production Technology (2021-2026)
2.4.3.3 Global Gesagliflozin Sale Price by Production Technology (2021-2026)
2.5 Gesagliflozin Segment by Sales Channels
2.5.1 Hospital
2.5.2 Retail
2.5.3 Online
2.5.4 Gesagliflozin Sales by Sales Channels
2.5.4.1 Global Gesagliflozin Sales Market Share by Sales Channels (2021-2026)
2.5.4.2 Global Gesagliflozin Revenue and Market Share by Sales Channels (2021-2026)
2.5.4.3 Global Gesagliflozin Sale Price by Sales Channels (2021-2026)
2.6 Gesagliflozin Segment by Application
2.6.1 KRAS G12C-Mutant Tumors
2.6.2 Non-Small Cell Lung Cancer (NSCLC)
2.6.3 Colorectal Cancer
2.6.4 Pancreatic Cancer
2.6.5 Others
2.6.6 Gesagliflozin Sales by Application
2.6.6.1 Global Gesagliflozin Sale Market Share by Application (2021-2026)
2.6.6.2 Global Gesagliflozin Revenue and Market Share by Application (2021-2026)
2.6.6.3 Global Gesagliflozin Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Gesagliflozin Breakdown Data by Company
3.1.1 Global Gesagliflozin Annual Sales by Company (2021-2026)
3.1.2 Global Gesagliflozin Sales Market Share by Company (2021-2026)
3.2 Global Gesagliflozin Annual Revenue by Company (2021-2026)
3.2.1 Global Gesagliflozin Revenue by Company (2021-2026)
3.2.2 Global Gesagliflozin Revenue Market Share by Company (2021-2026)
3.3 Global Gesagliflozin Sale Price by Company
3.4 Key Manufacturers Gesagliflozin Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Gesagliflozin Product Location Distribution
3.4.2 Players Gesagliflozin Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR GESAGLIFLOZIN BY GEOGRAPHIC REGION
4.1 World Historic Gesagliflozin Market Size by Geographic Region (2021-2026)
4.1.1 Global Gesagliflozin Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Gesagliflozin Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Gesagliflozin Market Size by Country/Region (2021-2026)
4.2.1 Global Gesagliflozin Annual Sales by Country/Region (2021-2026)
4.2.2 Global Gesagliflozin Annual Revenue by Country/Region (2021-2026)
4.3 Americas Gesagliflozin Sales Growth
4.4 APAC Gesagliflozin Sales Growth
4.5 Europe Gesagliflozin Sales Growth
4.6 Middle East & Africa Gesagliflozin Sales Growth
5 AMERICAS
5.1 Americas Gesagliflozin Sales by Country
5.1.1 Americas Gesagliflozin Sales by Country (2021-2026)
5.1.2 Americas Gesagliflozin Revenue by Country (2021-2026)
5.2 Americas Gesagliflozin Sales by Type (2021-2026)
5.3 Americas Gesagliflozin Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Gesagliflozin Sales by Region
6.1.1 APAC Gesagliflozin Sales by Region (2021-2026)
6.1.2 APAC Gesagliflozin Revenue by Region (2021-2026)
6.2 APAC Gesagliflozin Sales by Type (2021-2026)
6.3 APAC Gesagliflozin Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Gesagliflozin by Country
7.1.1 Europe Gesagliflozin Sales by Country (2021-2026)
7.1.2 Europe Gesagliflozin Revenue by Country (2021-2026)
7.2 Europe Gesagliflozin Sales by Type (2021-2026)
7.3 Europe Gesagliflozin Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Gesagliflozin by Country
8.1.1 Middle East & Africa Gesagliflozin Sales by Country (2021-2026)
8.1.2 Middle East & Africa Gesagliflozin Revenue by Country (2021-2026)
8.2 Middle East & Africa Gesagliflozin Sales by Type (2021-2026)
8.3 Middle East & Africa Gesagliflozin Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Gesagliflozin
10.3 Manufacturing Process Analysis of Gesagliflozin
10.4 Industry Chain Structure of Gesagliflozin
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Gesagliflozin Distributors
11.3 Gesagliflozin Customer
12 WORLD FORECAST REVIEW FOR GESAGLIFLOZIN BY GEOGRAPHIC REGION
12.1 Global Gesagliflozin Market Size Forecast by Region
12.1.1 Global Gesagliflozin Forecast by Region (2027-2032)
12.1.2 Global Gesagliflozin Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Gesagliflozin Forecast by Type (2027-2032)
12.7 Global Gesagliflozin Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 InventisBio
13.1.1 InventisBio Company Information
13.1.2 InventisBio Gesagliflozin Product Portfolios and Specifications
13.1.3 InventisBio Gesagliflozin Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 InventisBio Main Business Overview
13.1.5 InventisBio Latest Developments
13.2 Shanghai Chia Tai Tianqing Pharmaceutical
13.2.1 Shanghai Chia Tai Tianqing Pharmaceutical Company Information
13.2.2 Shanghai Chia Tai Tianqing Pharmaceutical Gesagliflozin Product Portfolios and Specifications
13.2.3 Shanghai Chia Tai Tianqing Pharmaceutical Gesagliflozin Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Shanghai Chia Tai Tianqing Pharmaceutical Main Business Overview
13.2.5 Shanghai Chia Tai Tianqing Pharmaceutical Latest Developments
13.3 WuXi AppTec Pharmaceutical
13.3.1 WuXi AppTec Pharmaceutical Company Information
13.3.2 WuXi AppTec Pharmaceutical Gesagliflozin Product Portfolios and Specifications
13.3.3 WuXi AppTec Pharmaceutical Gesagliflozin Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 WuXi AppTec Pharmaceutical Main Business Overview
13.3.5 WuXi AppTec Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Gesagliflozin Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Gesagliflozin Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of 100mg
Table 4. Major Players of 200mg
Table 5. Global Gesagliflozin Sales by Type (2021-2026) & (Units)
Table 6. Global Gesagliflozin Sales Market Share by Type (2021-2026)
Table 7. Global Gesagliflozin Revenue by Type (2021-2026) & ($ million)
Table 8. Global Gesagliflozin Revenue Market Share by Type (2021-2026)
Table 9. Global Gesagliflozin Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Major Players of Garsorasib and Immune Checkpoint Inhibitors
Table 11. Major Players of Garsorasib and FAK Inhibitors
Table 12. Global Gesagliflozin Sales by Combination Therapy (2021-2026) & (Units)
Table 13. Global Gesagliflozin Sales Market Share by Combination Therapy (2021-2026)
Table 14. Global Gesagliflozin Revenue by Combination Therapy (2021-2026) & ($ million)
Table 15. Global Gesagliflozin Revenue Market Share by Combination Therapy (2021-2026)
Table 16. Global Gesagliflozin Sale Price by Combination Therapy (2021-2026) & (US$/Unit)
Table 17. Major Players of Innovator
Table 18. Major Players of Generic
Table 19. Global Gesagliflozin Sales by Production Technology (2021-2026) & (Units)
Table 20. Global Gesagliflozin Sales Market Share by Production Technology (2021-2026)
Table 21. Global Gesagliflozin Revenue by Production Technology (2021-2026) & ($ million)
Table 22. Global Gesagliflozin Revenue Market Share by Production Technology (2021-2026)
Table 23. Global Gesagliflozin Sale Price by Production Technology (2021-2026) & (US$/Unit)
Table 24. Major Players of Hospital
Table 25. Major Players of Retail
Table 26. Major Players of Online
Table 27. Global Gesagliflozin Sales by Sales Channels (2021-2026) & (Units)
Table 28. Global Gesagliflozin Sales Market Share by Sales Channels (2021-2026)
Table 29. Global Gesagliflozin Revenue by Sales Channels (2021-2026) & ($ million)
Table 30. Global Gesagliflozin Revenue Market Share by Sales Channels (2021-2026)
Table 31. Global Gesagliflozin Sale Price by Sales Channels (2021-2026) & (US$/Unit)
Table 32. Global Gesagliflozin Sale by Application (2021-2026) & (Units)
Table 33. Global Gesagliflozin Sale Market Share by Application (2021-2026)
Table 34. Global Gesagliflozin Revenue by Application (2021-2026) & ($ million)
Table 35. Global Gesagliflozin Revenue Market Share by Application (2021-2026)
Table 36. Global Gesagliflozin Sale Price by Application (2021-2026) & (US$/Unit)
Table 37. Global Gesagliflozin Sales by Company (2021-2026) & (Units)
Table 38. Global Gesagliflozin Sales Market Share by Company (2021-2026)
Table 39. Global Gesagliflozin Revenue by Company (2021-2026) & ($ millions)
Table 40. Global Gesagliflozin Revenue Market Share by Company (2021-2026)
Table 41. Global Gesagliflozin Sale Price by Company (2021-2026) & (US$/Unit)
Table 42. Key Manufacturers Gesagliflozin Producing Area Distribution and Sales Area
Table 43. Players Gesagliflozin Products Offered
Table 44. Gesagliflozin Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 45. New Products and Potential Entrants
Table 46. Market M&A Activity & Strategy
Table 47. Global Gesagliflozin Sales by Geographic Region (2021-2026) & (Units)
Table 48. Global Gesagliflozin Sales Market Share Geographic Region (2021-2026)
Table 49. Global Gesagliflozin Revenue by Geographic Region (2021-2026) & ($ millions)
Table 50. Global Gesagliflozin Revenue Market Share by Geographic Region (2021-2026)
Table 51. Global Gesagliflozin Sales by Country/Region (2021-2026) & (Units)
Table 52. Global Gesagliflozin Sales Market Share by Country/Region (2021-2026)
Table 53. Global Gesagliflozin Revenue by Country/Region (2021-2026) & ($ millions)
Table 54. Global Gesagliflozin Revenue Market Share by Country/Region (2021-2026)
Table 55. Americas Gesagliflozin Sales by Country (2021-2026) & (Units)
Table 56. Americas Gesagliflozin Sales Market Share by Country (2021-2026)
Table 57. Americas Gesagliflozin Revenue by Country (2021-2026) & ($ millions)
Table 58. Americas Gesagliflozin Sales by Type (2021-2026) & (Units)
Table 59. Americas Gesagliflozin Sales by Application (2021-2026) & (Units)
Table 60. APAC Gesagliflozin Sales by Region (2021-2026) & (Units)
Table 61. APAC Gesagliflozin Sales Market Share by Region (2021-2026)
Table 62. APAC Gesagliflozin Revenue by Region (2021-2026) & ($ millions)
Table 63. APAC Gesagliflozin Sales by Type (2021-2026) & (Units)
Table 64. APAC Gesagliflozin Sales by Application (2021-2026) & (Units)
Table 65. Europe Gesagliflozin Sales by Country (2021-2026) & (Units)
Table 66. Europe Gesagliflozin Revenue by Country (2021-2026) & ($ millions)
Table 67. Europe Gesagliflozin Sales by Type (2021-2026) & (Units)
Table 68. Europe Gesagliflozin Sales by Application (2021-2026) & (Units)
Table 69. Middle East & Africa Gesagliflozin Sales by Country (2021-2026) & (Units)
Table 70. Middle East & Africa Gesagliflozin Revenue Market Share by Country (2021-2026)
Table 71. Middle East & Africa Gesagliflozin Sales by Type (2021-2026) & (Units)
Table 72. Middle East & Africa Gesagliflozin Sales by Application (2021-2026) & (Units)
Table 73. Key Market Drivers & Growth Opportunities of Gesagliflozin
Table 74. Key Market Challenges & Risks of Gesagliflozin
Table 75. Key Industry Trends of Gesagliflozin
Table 76. Gesagliflozin Raw Material
Table 77. Key Suppliers of Raw Materials
Table 78. Gesagliflozin Distributors List
Table 79. Gesagliflozin Customer List
Table 80. Global Gesagliflozin Sales Forecast by Region (2027-2032) & (Units)
Table 81. Global Gesagliflozin Revenue Forecast by Region (2027-2032) & ($ millions)
Table 82. Americas Gesagliflozin Sales Forecast by Country (2027-2032) & (Units)
Table 83. Americas Gesagliflozin Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 84. APAC Gesagliflozin Sales Forecast by Region (2027-2032) & (Units)
Table 85. APAC Gesagliflozin Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 86. Europe Gesagliflozin Sales Forecast by Country (2027-2032) & (Units)
Table 87. Europe Gesagliflozin Revenue Forecast by Country (2027-2032) & ($ millions)
Table 88. Middle East & Africa Gesagliflozin Sales Forecast by Country (2027-2032) & (Units)
Table 89. Middle East & Africa Gesagliflozin Revenue Forecast by Country (2027-2032) & ($ millions)
Table 90. Global Gesagliflozin Sales Forecast by Type (2027-2032) & (Units)
Table 91. Global Gesagliflozin Revenue Forecast by Type (2027-2032) & ($ millions)
Table 92. Global Gesagliflozin Sales Forecast by Application (2027-2032) & (Units)
Table 93. Global Gesagliflozin Revenue Forecast by Application (2027-2032) & ($ millions)
Table 94. InventisBio Basic Information, Gesagliflozin Manufacturing Base, Sales Area and Its Competitors
Table 95. InventisBio Gesagliflozin Product Portfolios and Specifications
Table 96. InventisBio Gesagliflozin Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. InventisBio Main Business
Table 98. InventisBio Latest Developments
Table 99. Shanghai Chia Tai Tianqing Pharmaceutical Basic Information, Gesagliflozin Manufacturing Base, Sales Area and Its Competitors
Table 100. Shanghai Chia Tai Tianqing Pharmaceutical Gesagliflozin Product Portfolios and Specifications
Table 101. Shanghai Chia Tai Tianqing Pharmaceutical Gesagliflozin Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. Shanghai Chia Tai Tianqing Pharmaceutical Main Business
Table 103. Shanghai Chia Tai Tianqing Pharmaceutical Latest Developments
Table 104. WuXi AppTec Pharmaceutical Basic Information, Gesagliflozin Manufacturing Base, Sales Area and Its Competitors
Table 105. WuXi AppTec Pharmaceutical Gesagliflozin Product Portfolios and Specifications
Table 106. WuXi AppTec Pharmaceutical Gesagliflozin Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. WuXi AppTec Pharmaceutical Main Business
Table 108. WuXi AppTec Pharmaceutical Latest Developments
Table 1. Gesagliflozin Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Gesagliflozin Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of 100mg
Table 4. Major Players of 200mg
Table 5. Global Gesagliflozin Sales by Type (2021-2026) & (Units)
Table 6. Global Gesagliflozin Sales Market Share by Type (2021-2026)
Table 7. Global Gesagliflozin Revenue by Type (2021-2026) & ($ million)
Table 8. Global Gesagliflozin Revenue Market Share by Type (2021-2026)
Table 9. Global Gesagliflozin Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Major Players of Garsorasib and Immune Checkpoint Inhibitors
Table 11. Major Players of Garsorasib and FAK Inhibitors
Table 12. Global Gesagliflozin Sales by Combination Therapy (2021-2026) & (Units)
Table 13. Global Gesagliflozin Sales Market Share by Combination Therapy (2021-2026)
Table 14. Global Gesagliflozin Revenue by Combination Therapy (2021-2026) & ($ million)
Table 15. Global Gesagliflozin Revenue Market Share by Combination Therapy (2021-2026)
Table 16. Global Gesagliflozin Sale Price by Combination Therapy (2021-2026) & (US$/Unit)
Table 17. Major Players of Innovator
Table 18. Major Players of Generic
Table 19. Global Gesagliflozin Sales by Production Technology (2021-2026) & (Units)
Table 20. Global Gesagliflozin Sales Market Share by Production Technology (2021-2026)
Table 21. Global Gesagliflozin Revenue by Production Technology (2021-2026) & ($ million)
Table 22. Global Gesagliflozin Revenue Market Share by Production Technology (2021-2026)
Table 23. Global Gesagliflozin Sale Price by Production Technology (2021-2026) & (US$/Unit)
Table 24. Major Players of Hospital
Table 25. Major Players of Retail
Table 26. Major Players of Online
Table 27. Global Gesagliflozin Sales by Sales Channels (2021-2026) & (Units)
Table 28. Global Gesagliflozin Sales Market Share by Sales Channels (2021-2026)
Table 29. Global Gesagliflozin Revenue by Sales Channels (2021-2026) & ($ million)
Table 30. Global Gesagliflozin Revenue Market Share by Sales Channels (2021-2026)
Table 31. Global Gesagliflozin Sale Price by Sales Channels (2021-2026) & (US$/Unit)
Table 32. Global Gesagliflozin Sale by Application (2021-2026) & (Units)
Table 33. Global Gesagliflozin Sale Market Share by Application (2021-2026)
Table 34. Global Gesagliflozin Revenue by Application (2021-2026) & ($ million)
Table 35. Global Gesagliflozin Revenue Market Share by Application (2021-2026)
Table 36. Global Gesagliflozin Sale Price by Application (2021-2026) & (US$/Unit)
Table 37. Global Gesagliflozin Sales by Company (2021-2026) & (Units)
Table 38. Global Gesagliflozin Sales Market Share by Company (2021-2026)
Table 39. Global Gesagliflozin Revenue by Company (2021-2026) & ($ millions)
Table 40. Global Gesagliflozin Revenue Market Share by Company (2021-2026)
Table 41. Global Gesagliflozin Sale Price by Company (2021-2026) & (US$/Unit)
Table 42. Key Manufacturers Gesagliflozin Producing Area Distribution and Sales Area
Table 43. Players Gesagliflozin Products Offered
Table 44. Gesagliflozin Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 45. New Products and Potential Entrants
Table 46. Market M&A Activity & Strategy
Table 47. Global Gesagliflozin Sales by Geographic Region (2021-2026) & (Units)
Table 48. Global Gesagliflozin Sales Market Share Geographic Region (2021-2026)
Table 49. Global Gesagliflozin Revenue by Geographic Region (2021-2026) & ($ millions)
Table 50. Global Gesagliflozin Revenue Market Share by Geographic Region (2021-2026)
Table 51. Global Gesagliflozin Sales by Country/Region (2021-2026) & (Units)
Table 52. Global Gesagliflozin Sales Market Share by Country/Region (2021-2026)
Table 53. Global Gesagliflozin Revenue by Country/Region (2021-2026) & ($ millions)
Table 54. Global Gesagliflozin Revenue Market Share by Country/Region (2021-2026)
Table 55. Americas Gesagliflozin Sales by Country (2021-2026) & (Units)
Table 56. Americas Gesagliflozin Sales Market Share by Country (2021-2026)
Table 57. Americas Gesagliflozin Revenue by Country (2021-2026) & ($ millions)
Table 58. Americas Gesagliflozin Sales by Type (2021-2026) & (Units)
Table 59. Americas Gesagliflozin Sales by Application (2021-2026) & (Units)
Table 60. APAC Gesagliflozin Sales by Region (2021-2026) & (Units)
Table 61. APAC Gesagliflozin Sales Market Share by Region (2021-2026)
Table 62. APAC Gesagliflozin Revenue by Region (2021-2026) & ($ millions)
Table 63. APAC Gesagliflozin Sales by Type (2021-2026) & (Units)
Table 64. APAC Gesagliflozin Sales by Application (2021-2026) & (Units)
Table 65. Europe Gesagliflozin Sales by Country (2021-2026) & (Units)
Table 66. Europe Gesagliflozin Revenue by Country (2021-2026) & ($ millions)
Table 67. Europe Gesagliflozin Sales by Type (2021-2026) & (Units)
Table 68. Europe Gesagliflozin Sales by Application (2021-2026) & (Units)
Table 69. Middle East & Africa Gesagliflozin Sales by Country (2021-2026) & (Units)
Table 70. Middle East & Africa Gesagliflozin Revenue Market Share by Country (2021-2026)
Table 71. Middle East & Africa Gesagliflozin Sales by Type (2021-2026) & (Units)
Table 72. Middle East & Africa Gesagliflozin Sales by Application (2021-2026) & (Units)
Table 73. Key Market Drivers & Growth Opportunities of Gesagliflozin
Table 74. Key Market Challenges & Risks of Gesagliflozin
Table 75. Key Industry Trends of Gesagliflozin
Table 76. Gesagliflozin Raw Material
Table 77. Key Suppliers of Raw Materials
Table 78. Gesagliflozin Distributors List
Table 79. Gesagliflozin Customer List
Table 80. Global Gesagliflozin Sales Forecast by Region (2027-2032) & (Units)
Table 81. Global Gesagliflozin Revenue Forecast by Region (2027-2032) & ($ millions)
Table 82. Americas Gesagliflozin Sales Forecast by Country (2027-2032) & (Units)
Table 83. Americas Gesagliflozin Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 84. APAC Gesagliflozin Sales Forecast by Region (2027-2032) & (Units)
Table 85. APAC Gesagliflozin Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 86. Europe Gesagliflozin Sales Forecast by Country (2027-2032) & (Units)
Table 87. Europe Gesagliflozin Revenue Forecast by Country (2027-2032) & ($ millions)
Table 88. Middle East & Africa Gesagliflozin Sales Forecast by Country (2027-2032) & (Units)
Table 89. Middle East & Africa Gesagliflozin Revenue Forecast by Country (2027-2032) & ($ millions)
Table 90. Global Gesagliflozin Sales Forecast by Type (2027-2032) & (Units)
Table 91. Global Gesagliflozin Revenue Forecast by Type (2027-2032) & ($ millions)
Table 92. Global Gesagliflozin Sales Forecast by Application (2027-2032) & (Units)
Table 93. Global Gesagliflozin Revenue Forecast by Application (2027-2032) & ($ millions)
Table 94. InventisBio Basic Information, Gesagliflozin Manufacturing Base, Sales Area and Its Competitors
Table 95. InventisBio Gesagliflozin Product Portfolios and Specifications
Table 96. InventisBio Gesagliflozin Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. InventisBio Main Business
Table 98. InventisBio Latest Developments
Table 99. Shanghai Chia Tai Tianqing Pharmaceutical Basic Information, Gesagliflozin Manufacturing Base, Sales Area and Its Competitors
Table 100. Shanghai Chia Tai Tianqing Pharmaceutical Gesagliflozin Product Portfolios and Specifications
Table 101. Shanghai Chia Tai Tianqing Pharmaceutical Gesagliflozin Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. Shanghai Chia Tai Tianqing Pharmaceutical Main Business
Table 103. Shanghai Chia Tai Tianqing Pharmaceutical Latest Developments
Table 104. WuXi AppTec Pharmaceutical Basic Information, Gesagliflozin Manufacturing Base, Sales Area and Its Competitors
Table 105. WuXi AppTec Pharmaceutical Gesagliflozin Product Portfolios and Specifications
Table 106. WuXi AppTec Pharmaceutical Gesagliflozin Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. WuXi AppTec Pharmaceutical Main Business
Table 108. WuXi AppTec Pharmaceutical Latest Developments
LIST OF FIGURES
Figure 1. Picture of Gesagliflozin
Figure 2. Gesagliflozin Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Gesagliflozin Sales Growth Rate 2021-2032 (Units)
Figure 7. Global Gesagliflozin Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Gesagliflozin Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Gesagliflozin Sales Market Share by Country/Region (2025)
Figure 10. Gesagliflozin Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of 100mg
Figure 12. Product Picture of 200mg
Figure 13. Global Gesagliflozin Sales Market Share by Type in 2026
Figure 14. Global Gesagliflozin Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of Garsorasib and Immune Checkpoint Inhibitors
Figure 16. Product Picture of Garsorasib and FAK Inhibitors
Figure 17. Global Gesagliflozin Sales Market Share by Combination Therapy in 2026
Figure 18. Global Gesagliflozin Revenue Market Share by Combination Therapy (2021-2026)
Figure 19. Product Picture of Innovator
Figure 20. Product Picture of Generic
Figure 21. Global Gesagliflozin Sales Market Share by Production Technology in 2026
Figure 22. Global Gesagliflozin Revenue Market Share by Production Technology (2021-2026)
Figure 23. Product Picture of Hospital
Figure 24. Product Picture of Retail
Figure 25. Product Picture of Online
Figure 26. Global Gesagliflozin Sales Market Share by Sales Channels in 2026
Figure 27. Global Gesagliflozin Revenue Market Share by Sales Channels (2021-2026)
Figure 28. Gesagliflozin Consumed in KRAS G12C-Mutant Tumors
Figure 29. Global Gesagliflozin Market: KRAS G12C-Mutant Tumors (2021-2026) & (Units)
Figure 30. Gesagliflozin Consumed in Non-Small Cell Lung Cancer (NSCLC)
Figure 31. Global Gesagliflozin Market: Non-Small Cell Lung Cancer (NSCLC) (2021-2026) & (Units)
Figure 32. Gesagliflozin Consumed in Colorectal Cancer
Figure 33. Global Gesagliflozin Market: Colorectal Cancer (2021-2026) & (Units)
Figure 34. Gesagliflozin Consumed in Pancreatic Cancer
Figure 35. Global Gesagliflozin Market: Pancreatic Cancer (2021-2026) & (Units)
Figure 36. Gesagliflozin Consumed in Others
Figure 37. Global Gesagliflozin Market: Others (2021-2026) & (Units)
Figure 38. Global Gesagliflozin Sale Market Share by Application (2025)
Figure 39. Global Gesagliflozin Revenue Market Share by Application in 2025
Figure 40. Gesagliflozin Sales by Company in 2025 (Units)
Figure 41. Global Gesagliflozin Sales Market Share by Company in 2025
Figure 42. Gesagliflozin Revenue by Company in 2025 ($ millions)
Figure 43. Global Gesagliflozin Revenue Market Share by Company in 2025
Figure 44. Global Gesagliflozin Sales Market Share by Geographic Region (2021-2026)
Figure 45. Global Gesagliflozin Revenue Market Share by Geographic Region in 2025
Figure 46. Americas Gesagliflozin Sales 2021-2026 (Units)
Figure 47. Americas Gesagliflozin Revenue 2021-2026 ($ millions)
Figure 48. APAC Gesagliflozin Sales 2021-2026 (Units)
Figure 49. APAC Gesagliflozin Revenue 2021-2026 ($ millions)
Figure 50. Europe Gesagliflozin Sales 2021-2026 (Units)
Figure 51. Europe Gesagliflozin Revenue 2021-2026 ($ millions)
Figure 52. Middle East & Africa Gesagliflozin Sales 2021-2026 (Units)
Figure 53. Middle East & Africa Gesagliflozin Revenue 2021-2026 ($ millions)
Figure 54. Americas Gesagliflozin Sales Market Share by Country in 2025
Figure 55. Americas Gesagliflozin Revenue Market Share by Country (2021-2026)
Figure 56. Americas Gesagliflozin Sales Market Share by Type (2021-2026)
Figure 57. Americas Gesagliflozin Sales Market Share by Application (2021-2026)
Figure 58. United States Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 59. Canada Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 60. Mexico Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 61. Brazil Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 62. APAC Gesagliflozin Sales Market Share by Region in 2025
Figure 63. APAC Gesagliflozin Revenue Market Share by Region (2021-2026)
Figure 64. APAC Gesagliflozin Sales Market Share by Type (2021-2026)
Figure 65. APAC Gesagliflozin Sales Market Share by Application (2021-2026)
Figure 66. China Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 67. Japan Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 68. South Korea Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 69. Southeast Asia Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 70. India Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 71. Australia Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 72. China Taiwan Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 73. Europe Gesagliflozin Sales Market Share by Country in 2025
Figure 74. Europe Gesagliflozin Revenue Market Share by Country (2021-2026)
Figure 75. Europe Gesagliflozin Sales Market Share by Type (2021-2026)
Figure 76. Europe Gesagliflozin Sales Market Share by Application (2021-2026)
Figure 77. Germany Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 78. France Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 79. UK Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 80. Italy Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 81. Russia Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 82. Middle East & Africa Gesagliflozin Sales Market Share by Country (2021-2026)
Figure 83. Middle East & Africa Gesagliflozin Sales Market Share by Type (2021-2026)
Figure 84. Middle East & Africa Gesagliflozin Sales Market Share by Application (2021-2026)
Figure 85. Egypt Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 86. South Africa Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 87. Israel Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 88. Turkey Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 89. GCC Countries Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 90. Manufacturing Cost Structure Analysis of Gesagliflozin in 2026
Figure 91. Manufacturing Process Analysis of Gesagliflozin
Figure 92. Industry Chain Structure of Gesagliflozin
Figure 93. Channels of Distribution
Figure 94. Global Gesagliflozin Sales Market Forecast by Region (2027-2032)
Figure 95. Global Gesagliflozin Revenue Market Share Forecast by Region (2027-2032)
Figure 96. Global Gesagliflozin Sales Market Share Forecast by Type (2027-2032)
Figure 97. Global Gesagliflozin Revenue Market Share Forecast by Type (2027-2032)
Figure 98. Global Gesagliflozin Sales Market Share Forecast by Application (2027-2032)
Figure 99. Global Gesagliflozin Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Gesagliflozin
Figure 2. Gesagliflozin Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Gesagliflozin Sales Growth Rate 2021-2032 (Units)
Figure 7. Global Gesagliflozin Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Gesagliflozin Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Gesagliflozin Sales Market Share by Country/Region (2025)
Figure 10. Gesagliflozin Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of 100mg
Figure 12. Product Picture of 200mg
Figure 13. Global Gesagliflozin Sales Market Share by Type in 2026
Figure 14. Global Gesagliflozin Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of Garsorasib and Immune Checkpoint Inhibitors
Figure 16. Product Picture of Garsorasib and FAK Inhibitors
Figure 17. Global Gesagliflozin Sales Market Share by Combination Therapy in 2026
Figure 18. Global Gesagliflozin Revenue Market Share by Combination Therapy (2021-2026)
Figure 19. Product Picture of Innovator
Figure 20. Product Picture of Generic
Figure 21. Global Gesagliflozin Sales Market Share by Production Technology in 2026
Figure 22. Global Gesagliflozin Revenue Market Share by Production Technology (2021-2026)
Figure 23. Product Picture of Hospital
Figure 24. Product Picture of Retail
Figure 25. Product Picture of Online
Figure 26. Global Gesagliflozin Sales Market Share by Sales Channels in 2026
Figure 27. Global Gesagliflozin Revenue Market Share by Sales Channels (2021-2026)
Figure 28. Gesagliflozin Consumed in KRAS G12C-Mutant Tumors
Figure 29. Global Gesagliflozin Market: KRAS G12C-Mutant Tumors (2021-2026) & (Units)
Figure 30. Gesagliflozin Consumed in Non-Small Cell Lung Cancer (NSCLC)
Figure 31. Global Gesagliflozin Market: Non-Small Cell Lung Cancer (NSCLC) (2021-2026) & (Units)
Figure 32. Gesagliflozin Consumed in Colorectal Cancer
Figure 33. Global Gesagliflozin Market: Colorectal Cancer (2021-2026) & (Units)
Figure 34. Gesagliflozin Consumed in Pancreatic Cancer
Figure 35. Global Gesagliflozin Market: Pancreatic Cancer (2021-2026) & (Units)
Figure 36. Gesagliflozin Consumed in Others
Figure 37. Global Gesagliflozin Market: Others (2021-2026) & (Units)
Figure 38. Global Gesagliflozin Sale Market Share by Application (2025)
Figure 39. Global Gesagliflozin Revenue Market Share by Application in 2025
Figure 40. Gesagliflozin Sales by Company in 2025 (Units)
Figure 41. Global Gesagliflozin Sales Market Share by Company in 2025
Figure 42. Gesagliflozin Revenue by Company in 2025 ($ millions)
Figure 43. Global Gesagliflozin Revenue Market Share by Company in 2025
Figure 44. Global Gesagliflozin Sales Market Share by Geographic Region (2021-2026)
Figure 45. Global Gesagliflozin Revenue Market Share by Geographic Region in 2025
Figure 46. Americas Gesagliflozin Sales 2021-2026 (Units)
Figure 47. Americas Gesagliflozin Revenue 2021-2026 ($ millions)
Figure 48. APAC Gesagliflozin Sales 2021-2026 (Units)
Figure 49. APAC Gesagliflozin Revenue 2021-2026 ($ millions)
Figure 50. Europe Gesagliflozin Sales 2021-2026 (Units)
Figure 51. Europe Gesagliflozin Revenue 2021-2026 ($ millions)
Figure 52. Middle East & Africa Gesagliflozin Sales 2021-2026 (Units)
Figure 53. Middle East & Africa Gesagliflozin Revenue 2021-2026 ($ millions)
Figure 54. Americas Gesagliflozin Sales Market Share by Country in 2025
Figure 55. Americas Gesagliflozin Revenue Market Share by Country (2021-2026)
Figure 56. Americas Gesagliflozin Sales Market Share by Type (2021-2026)
Figure 57. Americas Gesagliflozin Sales Market Share by Application (2021-2026)
Figure 58. United States Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 59. Canada Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 60. Mexico Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 61. Brazil Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 62. APAC Gesagliflozin Sales Market Share by Region in 2025
Figure 63. APAC Gesagliflozin Revenue Market Share by Region (2021-2026)
Figure 64. APAC Gesagliflozin Sales Market Share by Type (2021-2026)
Figure 65. APAC Gesagliflozin Sales Market Share by Application (2021-2026)
Figure 66. China Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 67. Japan Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 68. South Korea Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 69. Southeast Asia Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 70. India Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 71. Australia Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 72. China Taiwan Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 73. Europe Gesagliflozin Sales Market Share by Country in 2025
Figure 74. Europe Gesagliflozin Revenue Market Share by Country (2021-2026)
Figure 75. Europe Gesagliflozin Sales Market Share by Type (2021-2026)
Figure 76. Europe Gesagliflozin Sales Market Share by Application (2021-2026)
Figure 77. Germany Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 78. France Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 79. UK Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 80. Italy Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 81. Russia Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 82. Middle East & Africa Gesagliflozin Sales Market Share by Country (2021-2026)
Figure 83. Middle East & Africa Gesagliflozin Sales Market Share by Type (2021-2026)
Figure 84. Middle East & Africa Gesagliflozin Sales Market Share by Application (2021-2026)
Figure 85. Egypt Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 86. South Africa Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 87. Israel Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 88. Turkey Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 89. GCC Countries Gesagliflozin Revenue Growth 2021-2026 ($ millions)
Figure 90. Manufacturing Cost Structure Analysis of Gesagliflozin in 2026
Figure 91. Manufacturing Process Analysis of Gesagliflozin
Figure 92. Industry Chain Structure of Gesagliflozin
Figure 93. Channels of Distribution
Figure 94. Global Gesagliflozin Sales Market Forecast by Region (2027-2032)
Figure 95. Global Gesagliflozin Revenue Market Share Forecast by Region (2027-2032)
Figure 96. Global Gesagliflozin Sales Market Share Forecast by Type (2027-2032)
Figure 97. Global Gesagliflozin Revenue Market Share Forecast by Type (2027-2032)
Figure 98. Global Gesagliflozin Sales Market Share Forecast by Application (2027-2032)
Figure 99. Global Gesagliflozin Revenue Market Share Forecast by Application (2027-2032)
